[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms]
- PMID: 16681930
[Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms]
Abstract
Objective: To investigate the effects of norcantharidin (NCTD) on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms.
Methods: Human gallbladder carcinoma cells of the line GBC-SD were cultured. BALB/c nude mice were inoculated subcutaneously with the GBC-SD cells and then randomly divided into 6 groups: NCTD group, injected intraperitoneally with 1/5 of the LD(50) of NCTD twice a week for 6 weeks; 5-fluorouracil (5-FU) group, injected intraperitoneally with 1/5 of the LD(50) of 5-FU twice a week for 6 weeks; endostatin (ES) group, intraperitoneally with ES; NCTD + 5-FU group, injected intraperitoneally with 1/5 of the LD(50) of NCTD and 1/5 of the LD(50) of 5-FU twice a week for 6 weeks; NCTD + ES group, injected intraperitoneally with 1/5 of the LD(50) of NCTD and ES twice a week for 6 weeks; and normal saline (NS) group (control group), injected with NS. The mice were killed in the 7th week. The tumors were taken out to measure their volumes and undergo microscopy. SABC method of immunohistochemistry was used to measure the microvessel density (MVD) and the protein expression of the angiogenesis-related factors: proliferating cell nuclear antigen (PCNA), vascular endothelial growth factor (VEGF), angiopoietin (Ang)-2, thrombospondin (TSP), and tissue inhibitor of metalloprotease (TIMP)(2). Suspension of single tumor cell was prepared to examine the cell apoptosis by flow cytometry. RT-PCR was used to examine the mRNA expression of PCNA, VEGF, Ang-2, TSP, and TIMP2.
Results: (1) The MVD of the NCTD group was 4.12 +/- 1.4, significantly lower than those of the 5-FU group (15.8 +/- 5.9) and control group (17.6 +/- 3.2) (both P < 0.01), but not significantly different from those of the NCTD + 5-FU group (3.8 +/- 1.7), ES group (4.5 +/- 2.1), and NCTD + ES group (2.9 +/- 1.5) (all P > 0.05). The mice treated with NCTD showed significantly smaller tumor volume, lower PCNA protein expression, higher apoptotic rate, and higher PCNA/apoptosis ratio (P < 0.05 or P < 0.01), and significant correlation between MVD and tumor volume and between MVD and PCNA/apoptosis ratio (both P < 0.05). (2) The protein expression of VEGF and of Ang-2 of the NCTD group were both significantly lower than those of the control and 5-FU groups (all P < 0.01), however, not significantly different from those of the ES, NCTD + 5-FU, and NCTD + ES groups; and the protein expression of TSP and of TIMP2 of the NCTD group were both significantly higher than those of the control and 5-FU groups (all P < 0.01), however, not significantly different from those of the ES, NCTD + 5-FU, and NCTD + ES groups. MVD was positively correlated with VEGF and Ang-2 expression and negatively correlated with the expression of TSP and TIMP2 (all P < 0.05). (3) In comparison with the control group, the mRNA expression of VEGF and of Ang-2 of the tumor cells of the NCTD group were both significantly lower and the mRNA expression of TIMP2 was significantly higher.
Conclusion: NCTD down-regulates the expression of the angiogenic factors, such as VEF|GF and Ang-2, and up-regulates the expression of the anti-angiogenic factors, such as TDP and TIMP2, thus inhibiting the angiogenesis in tumor, such as human gallbladder carcinoma, and further inhibiting the growth of tumor.
Similar articles
-
Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.Int J Oncol. 2012 May;40(5):1501-14. doi: 10.3892/ijo.2011.1314. Epub 2011 Dec 21. Int J Oncol. 2012. PMID: 22200632
-
[Anti-tumor mechanism of norcantharidin for the implanted tumors of human gallbladder carcinoma in nude mice in vivo].Zhonghua Wai Ke Za Zhi. 2006 May 1;44(9):618-22. Zhonghua Wai Ke Za Zhi. 2006. PMID: 16784656 Chinese.
-
Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo.Hepatobiliary Pancreat Dis Int. 2010 Aug;9(4):414-22. Hepatobiliary Pancreat Dis Int. 2010. PMID: 20688607
-
Ang-1 and VEGF: central regulators of angiogenesis.Mol Cell Biochem. 2025 Feb;480(2):621-637. doi: 10.1007/s11010-024-05010-3. Epub 2024 Apr 23. Mol Cell Biochem. 2025. PMID: 38652215 Review.
-
Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years.Biomed Pharmacother. 2020 Nov;131:110755. doi: 10.1016/j.biopha.2020.110755. Epub 2020 Sep 25. Biomed Pharmacother. 2020. PMID: 33152920 Review.
Cited by
-
Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.PLoS One. 2014 May 8;9(5):e96982. doi: 10.1371/journal.pone.0096982. eCollection 2014. PLoS One. 2014. Retraction in: PLoS One. 2025 Feb 20;20(2):e0319593. doi: 10.1371/journal.pone.0319593. PMID: 24811250 Free PMC article. Retracted.
-
Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.Chin Med. 2020 May 29;15:55. doi: 10.1186/s13020-020-00338-6. eCollection 2020. Chin Med. 2020. PMID: 32514288 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous